Scott Goldsmith, MD

The closing discussion brings together the emerging clinical evidence and future development of CELMoDs in multiple myeloma.

The second clinical scenario considers a 72-year-old patient with multiple myeloma who is triple-class exposed and has experienced disease progression after a BCMA-directed T-cell-engaging therapy.

The discussion continues with the first clinical scenario involving lenalidomide-refractory multiple myeloma.

The first clinical scenario focuses on a 66-year-old patient with multiple myeloma who develops biochemical progression during lenalidomide maintenance after frontline therapy and autologous stem cell transplantation.

The discussion expands to investigational CELMoDs in multiple myeloma, focusing on cemsidomide and the ongoing MOMENTUM trial.

The discussion turns to the immunomodulatory effects of CELMoDs in multiple myeloma, with Dr. Goldsmith describing preclinical evidence suggesting that CELMoDs can enhance T-cell and NK-cell activity through effects on cytokine signaling and immune-mediated mechanisms.

Dr. Mikhael asks Dr. Goldsmith to further explain the clinical relevance of the differences in cereblon engagement between CELMoDs and established IMiDs for clinicians treating multiple myeloma.

Dr. Mikhael begins the scientific foundation by asking Dr. Richardson to define CELMoDs and explain how they engage the cereblon E3 ubiquitin ligase complex to promote targeted degradation of Ikaros and Aiolos, key transcription factors involved in myeloma-cell biology.

Dr. Joseph Mikhael welcomes the audience to the Cancer Network Training Academy program and introduces Dr. Paul Richardson and Dr. Scott Goldsmith, who bring clinical and research expertise in multiple myeloma.